February 27, 2026
Quotient and Ipsen extend partnership for ultra-rare disease therapy
Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







